摘要
抗菌素耐药性对未来的医疗保健提供是一个重大的挑战。首字母缩略词ESKAPEE来源于生物公认的主要威胁的名字,虽然有许多其他的生物,特别是淋病奈瑟菌,已经在临床治疗同样具有挑战性。这些病原体的特点是能够迅速发展和/或获得耐药机制,以暴露于不同的抗菌剂。这些病原体的军械库的一个关键部分是一系列的外排泵,从而有效地排除或减少细胞内大量的抗生素浓度,使病原体更有耐药性。这些外排泵是相当重要的话题,无论是从基本的了解外排泵功能,和其作用的药物耐药性,还是作为新的辅助疗法的发展目标。克服抗菌素耐药性的必要性,鼓励调查的抗蚀性改变外排泵抑制剂,阻止药物挤压的机制,从而恢复抗菌药物的敏感性,并将现有的抗生素进入临床。一个更大的理解由多重耐药外排泵的药物识别和运输需要开发临床上有用的抑制剂,鉴于分子的宽度,可以由这些系统流出。本文综述了起源从天然来源和化学合成不同的细菌流出物射流泵抑制剂,探讨面临的挑战成功的流出物射流泵抑制剂,可以用于抗多药耐药菌的设计。
关键词: 抗菌素耐药性,外排泵抑制剂,合理的药物设计,药物化学优化,多排系统,计算方法。
Current Medicinal Chemistry
Title:Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps
Volume: 23 Issue: 10
Author(s): Hannah Y. Mahmood, Shirin Jamshidi, J. Mark Sutton, Khondaker M. Rahman
Affiliation:
关键词: 抗菌素耐药性,外排泵抑制剂,合理的药物设计,药物化学优化,多排系统,计算方法。
摘要:
Antimicrobial resistance represents a significant challenge to future healthcare provision.An acronym ESKAPEE has been derived from the names of the organisms recognised as the major threats although there are a number of other organisms, notably Neisseria gonorrhoeae, that have become equally challenging to treat in the clinic. These pathogens are characterised by the ability to rapidly develop and/or acquire resistance mechanisms in response to exposure to different antimicrobial agents. A key part of the armoury of these pathogens is a series of efflux pumps, which effectively exclude or reduce the intracellular concentration of a large number of antibiotics, making the pathogens significantly more resistant. These efflux pumps are the topic of considerable interest, both from the perspective of basic understanding of efflux pump function, and its role in drug resistance but also as targets for the development of novel adjunct therapies. The necessity to overcome antimicrobial resistance has encouraged investigations into the characterisation of resistance-modifying efflux pump inhibitors to block the mechanisms of drug extrusion, thereby restoring antibacterial susceptibility and returning existing antibiotics into the clinic. A greater understanding of drug recognition and transport by multidrug efflux pumps is needed to develop clinically useful inhibitors, given the breadth of molecules that can be effluxed by these systems. This review discusses different bacterial EPIs originating from both natural source and chemical synthesis and examines the challenges to designing successful EPIs that can be useful against multidrug resistant bacteria.
Export Options
About this article
Cite this article as:
Hannah Y. Mahmood, Shirin Jamshidi, J. Mark Sutton, Khondaker M. Rahman , Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps, Current Medicinal Chemistry 2016; 23 (10) . https://dx.doi.org/10.2174/0929867323666160304150522
DOI https://dx.doi.org/10.2174/0929867323666160304150522 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Listeria-Based Anti-Infective Vaccine Strategies
Recent Patents on Anti-Infective Drug Discovery Computational Biology Tools for Identifying Specific Ligand Binding Residues for Novel Agrochemical and Drug Design
Current Protein & Peptide Science Cannabinoid Signaling in Glial Cells in Health and Disease
Current Neuropharmacology Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Status Epilepticus: An Overview
Current Drug Metabolism The Possible Involvement of HLA Class III Haplotype (RAGE, HSP70 and TNF Genes) in Alzheimer's Disease
Current Alzheimer Research Multimodalities Imaging of Immunoglobulin 4-related Cardiovascular Disorders
Current Cardiology Reviews Bacterial Recognition and Induced Cell Activation in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Development and Validation of Microbiological Assay for Ceftriaxone and its Application in Photo-stability Study
Current Pharmaceutical Analysis Advances in Adjuvant Therapy Against Acute Bacterial Meningitis
Current Drug Targets - Infectious Disorders Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Antiretroviral and Antituberculosis Therapy in HIV-TB Co-Infected Children
Current Pediatric Reviews An Update on the Synthesis and Antibacterial Effects of Carbapenems
Recent Patents on Anti-Infective Drug Discovery Multivalent Presentation Strategies in Novel Inhibitors of Bacterial (Toxin) Adhesion and Synthetic Vaccines
Anti-Infective Agents in Medicinal Chemistry Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry